Tin tức & Cập nhật
Lọc theo Chuyên ngành:
Atezolizumab-chemo confers durable survival benefit in ES-SCLC
In the merged analysis of the IMpower133 trial and IMbrella A open-label extension study, the combination of the PD-L1 inhibitor atezolizumab and a chemotherapy regimen comprising carboplatin and etoposide (CP/ET) demonstrated potential for survival benefit of up to 5 years in patients with extensive stage-small-cell lung cancer (ES-SCLC).
Atezolizumab-chemo confers durable survival benefit in ES-SCLC
27 Sep 2023Passive smoking: Does it influence risk of childhood atopic eczema, food allergy?
A systematic review and meta-analysis from Singapore demonstrates that parental smoking is not a strong risk factor for offspring eczema, food allergy, and food sensitization development.
Passive smoking: Does it influence risk of childhood atopic eczema, food allergy?
26 Sep 2023Benralizumab helps maintain severe asthma control with reduced ICS doses
Treatment with benralizumab allows tapering of inhaled corticosteroid (ICS) doses for patients with severe eosinophilic asthma, without compromising disease control and increasing exacerbations, as shown in the results of the phase IV SHAMAL study.